Disclosures: Dr. Ferdinand is a consultant for Roche, Merck, Forest, Takeda, and Astra Zeneca, and has received research grants from Novartis and Daiichi Sankyo. He is an American Society of Hypertension Board of Directors member.
Obesity and hypertension: It's about more than the numbers†
Version of Record online: 25 MAY 2013
Copyright © 2013 The Obesity Society
Volume 21, Issue 4, pages 657–658, April 2013
How to Cite
Ferdinand, K. C. (2013), Obesity and hypertension: It's about more than the numbers. Obesity, 21: 657–658. doi: 10.1002/oby.20372
- Issue online: 25 MAY 2013
- Version of Record online: 25 MAY 2013
- Accepted manuscript online: 20 MAR 2013 02:03AM EST
- Manuscript Accepted: 4 JAN 2013
- Manuscript Received: 19 DEC 2012
- 1Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—A Position Paper of the Obesity Society and the American Society of Hypertension. Obesity 2012. doi:10.1038/oby.20181., , , et al.
- 5Revisitng the obesity paradox in heart failure: new insights. Eur J Heart Fail 2011. doi:10.1093/eurjh/, , .
- 8ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165( 12): 1401-1409., , , et al.;
- 10Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2012. doi: 10.1016/S0140–6736(12)61343–9., , , et al.